drugset / Trial / NCT02181426

Dose Response of Ketorolac in Knee Arthroscopy

NCT02181426

Completed 112 enrolled Medical University of South Carolina
RandomizedParallel-groupDouble-blindTreatment

Summary

Ketorolac is administered as current practice to the majority of patients undergoing knee arthroscopy, the appropriate dose of ketorolac to be administered has not been evaluated.

Timeline

Start
2012-03
Primary completion
2016-12-15
Completion
2016-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketorolac Other / unclassified 7.5 mg
Comparator Ketorolac Other / unclassified 15 mg
Comparator Ketorolac Other / unclassified 30 mg

Indications

No indication recorded.